Hepatocellular carcinoma (HCC) is one of the most common malignancy tumors and and the incidence and mortality of liver cancer in our country both rank first in the world. At present, the treatment methods for HCC are diverse, including surgical treatment (hepatectomy, liver transplantation), local ablation therapy, interventional therapy, radiation therapy, immunotherapy, targeted therapy, and chemotherapy.But these treatments both have requirements for the liver function of patients, because these treatments may cause damage to the liver function of patients with liver cancer more or less, and some patients with liver cancer are already at an advanced stage when they are discovered, and they already have liver damage. Therefore, it is very necessary to establish a simple and effective model that can evaluate the liver function of patients with liver cancer to guide its clinical efficacy and prognosis. Child⁃Pugh score is the most commonly used clinical method to evaluate liver function currently, and it has been already included in the BCLC staging system to guide the clinical treatment and prognosis of patients with liver cancer. However, it contains five indicators, albumin, total bilirubin, hepatic encephalopathy, ascites, and prothrombin time, they are not weighted, and ascites and hepatic encephalopathy are highly subjective. In addition, Albumin and ascites are also factors that affect each other, thereby reducing the objectivity and accuracy of the score. Albumin⁃bilirubin（ALBI）grade is a new method proposed in recent years to assess liver function. It only contains two objective indicators of albumin and bilirubin, which is simpler and more objective than Child⁃Pugh score. The specific calculation formula is ALBI=(log10 bilirubin×0.66)+(albumin×⁃0.085). According to the score, the patients with liver cancer are divided into three grades, ALBI grade 1: ALBI≤⁃2.60, ALBI grade 2: ⁃2.60⁃1.39, the higher the grade, the worse the liver function. In recent years, the role of ALBI grade in evaluating the efficacy and prognosis of patients with liver cancer has been universally verified. This review summarizes the research progress of ALBI grade in evaluating efficacy and prognosis of patients with liver cancer through liver transplantation, liver resection, liver radiofrequency ablation, hepatic artery chemoembolization and targeted therapy, and immunotherapy, as well as the combination of ALBI grade and other staging systems to assess the prognosis of patients with liver cancer